Warwick Medical School is delighted to welcome the new appointment of Professor Charles Craddock CBE to the Clinical Trials Unit as Professor of Haemato-Oncology.

Professor Craddock will take a lead role in developing high-quality research programmes in clinical and cost effectiveness research of cancer therapies and support the University’s work on Innovation particularly in the health theme including the development of the University’s supra-regional health innovation campus Arden Cross and other projects. Professor Craddock joins us from his previous position of Professor of Haemato-oncology at the University of Birmingham and the Academic Director of the Centre for Clinical Haematology at the Queen Elizabeth Hospital.

He trained in haematology at the Hammersmith Hospital in London, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, USA. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He was elected President of the British Society Of Haematology in 2017. He led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015 and in 2017 oversaw the £3.4m expansion of the Centre for Clinical Haematology at the Queen Elizabeth Hospital.

Professor Craddock’s main research interests include the development of novel drug and transplant therapies in myeloid leukaemia’s, and he leads the UK Haemato-oncology Trials Acceleration Programme. He pioneered the development of a UK stem cell transplant trials network, IMPACT, one of only two worldwide, which was launched in 2017.

Warwick Medical School, Dean of Medicine, Professor Sudhesh Kumar said ‘We are delighted that Professor Craddock has joined WMS. He brings a wealth of expertise in Clinical Haematology and will strengthen the research capability within our Clinical Trials Unit. He has an excellent reputation internationally for his pioneering work in blood cancer, stem cell transplantation, and the development of internationally significant trials networks. His leadership and translational medicine expertise will be a great asset to the School as we look to develop our own regional health innovation agenda in this area.”

Professor Craddock said “I am thrilled to be joining Warwick Clinical Trials Unit at a time of such enormous therapeutic promise for patients with blood cancer and greatly look forward to working with colleagues to build innovative models of accelerated trial delivery on this exceptional health and medical sciences campus.”